Advanced NSCLC patients with c-Met amplification can respond to c-Met inhibitors. Unfortunately, the lack of adequate tissue often precludes c-Met testing. We hypothesized that plasma cell-free DNA (cfDNA) can offer an alternative source of biologic material for testing.
We designed a target region on exon 4 of c-Met gene, used RNaseP as the reference gene. We evaluated this c-Met:RNaseP ddPCR assay to determinate c-Met amplification in plasma cfDNA in 34 patients with advanced NSCLC who received c-Met inhibitor therapy, results were correlated with clinical findings.
The concordance rate of ddPCR with FISH was not high (55.9%); however, patients who were c-Met-positive by ddPCR had significantly longer PFS after c-Met inhibitor therapy compared with c-Met-negative patients (4.352 months and 1.657 months, respectively, P = 0.008).
Our results demonstrated that this ddPCR method can be used to evaluate c-Met status in plasma cfDNA samples. The c-Met status determined in cfDNA may have potential as a predictive factor for PFS after c-Met inhibitor therapy.
Clinical trial indentification
not a clinical trial
Legal entity responsible for the study
All authors have declared no conflicts of interest.